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Objectives This study sought to evaluate the long-term clinical outcome of patients with an angio-
graphically intermediate left anterior descending coronary artery (LAD) stenosis in whom the revas-
cularization strategy was based on fractional ﬂow reserve (FFR).
Background When revascularization is based mainly on angiographic guidance, a number of hemo-
dynamically nonsigniﬁcant stenoses will be revascularized.
Methods In 730 patients with a 30% to 70% isolated stenosis in the proximal LAD and no signiﬁ-
cant valvular disease, FFR measurements were obtained to guide treatment strategy. When FFR was
0.80, the patients (n  564) were treated medically (medical group); when FFR was 0.80, the
patients (n  166) underwent a revascularization procedure (revascularization group; 13% coronary
artery bypass graft surgery and 87% percutaneous coronary intervention). A 100% long-term clinical
follow-up (median follow-up: 40 months) was obtained. The 5-year survival of the medical group
was compared with that of a reference population. For each patient, 4 controls were selected from
an age- and sex-matched control population.
Results The 5-year survival estimate was 92.9% in the medical group versus 89.6% in the controls
(p  0.74). The mean diameter stenosis was signiﬁcantly smaller in the medical than in the revascu-
larization group (39  14% vs. 54  13%, p  0.0001), but there was a large overlap between both
groups. The 5-year event-free survival estimates (death, myocardial infarction, and target vessel re-
vascularization) were 89.7% and 68.5%, respectively (p  0.0001).
Conclusions Medical treatment of patients with a hemodynamically nonsigniﬁcant stenosis (FFR
0.80) in the proximal LAD is associated with an excellent long-term clinical outcome with survival
at 5 years similar to an age- and sex-matched control population. (J Am Coll Cardiol Intv 2011;4:
1175–82) © 2011 by the American College of Cardiology Foundation
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1176The presence of a significant narrowing in the proximal left
anterior descending coronary artery (LAD) is a generally
accepted indication for treatment by either coronary artery
bypass graft surgery (CABG) or percutaneous coronary
intervention (PCI) (1–3). Several small trials have compared
these modalities of revascularization in patients with iso-
lated stenoses in the proximal LAD (4–6). The very
definition of a significant stenosis is, however, rarely ques-
tioned. In most trials, the presence of a 50% diameter
stenosis by visual estimate in the proximal LAD has been a
sufficient criterion for the patient to be randomized. It is
now widely recognized that the angiogram is a poor tool to
gauge the functional significance of a coronary stenosis.
When revascularization is based mainly on angiographic
guidance, it is unavoidable that a number of hemodynami-
cally nonsignificant stenoses will be revascularized, whereas
a number of stenoses deemed nonsignificant will be deferred
inappropriately (7–9). Fractional flow reserve (FFR) is a
well-validated method to quan-
tify the impact of a coronary
stenosis on myocardial perfusion
(10,11). It is based on coronary
pressure measurements obtained
during maximal hyperemia. FFR
has a high spatial resolution (at
the level of a few millimeters)
and can be obtained in a few
minutes in the catheterization
laboratory, allowing an “on the
spot” decision about the appro-
priateness of revascularization
(8,12,13).
The aim of the present study
was to assess the long-term clin-
ical outcome of patients with an
angiographically equivocal LAD
stenosis and in whom the revascularization strategy was
based on the FFR.
Methods
Patient population. From 1999 to 2008, 6,107 patients with
table angina underwent coronary angiography and an FFR
easurement in at least 1 coronary artery at the Cardiovas-
ular Center, Aalst, Belgium. Among them, 852 patients
resented with a stenosis between 30% and 70% by visual
stimate in the proximal segment of the LAD (14,15) and
o other stenosis of more than 30% elsewhere in the
oronary tree. Patients presenting with a concomitant non-
ardiac life-threatening disease (n  35), those requiring
alvular surgery (n  42), and those in whom the referring
ardiologist decided not to take the FFR value into account
o guide the treatment (n  45) were not included in the
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CI  confidence interval
FFR  fractional flow
reserve
HR  hazard ratio
LAD  left anterior
descending coronary artery
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiographynalysis. In the remaining 730 patients, when FFR was0.80, patients were treated medically (“medical group,”
 564); When FFR was 0.80, patients were treated by
evascularization (“revascularization group,” n  166) (Fig. 1).
ll demographics and baseline clinical follow-up data were
etrieved from the local database.
Coronary angiography. Diagnostic left heart catheterization
nd coronary angiography were performed by a standard
ercutaneous femoral approach. After the diagnostic angio-
ram, a 6-F guiding catheter was introduced, and after
dministration of 200 g of intracoronary isosorbide dini-
trate, the angiogram was repeated in the projection allowing
the best possible visualization of the proximal LAD
stenosis.
In all patients, a visual estimate of the diameter stenosis
of the proximal LAD stenosis was made by the operator.
This value was used in the clinical report produced after the
diagnostic angiogram. This value was also used for patient
selection in the present study. In addition to this subjective
analysis, quantitative analysis was obtained offline in a
subset of 200 patients. Therefore, a computer-based analysis
system, Siemens QuantCor QCA (ACOM.PC 5.01, Sie-
6107 Patients had FFR 
measurement
1999-2008
852 patients with an isolated
proximal LAD stenosis
730 patients eligible for the 
study
166 patients with an FFR  
<0.80 and treated by 
revascularization
564 patients with an FFR  
≥0.80 and treated medically
35 patients had non-cardiac life-threatening disease
42 patients required valvular surgery
45 patients  in whom the operator decided not to take 
the FFR value into account to guide the treatment
Angiography
1. Proximal LAD stenosis  
>30%
2. Other vessel disease
<30%
Figure 1. Flow Chart of the Study
FFR  fractional ﬂow reserve; LAD  left anterior descending
coronary artery.mens Medical Systems Inc., Malvern, Pennsylvania) based
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1177on the CAAS II system (Pie Medical Imaging, Maastricht,
the Netherlands), was used. All quantitative coronary an-
giography (QCA) measurements were performed by 2
independent observers who were blinded to patient clinical
outcome and FFR data. The contrast-filled catheter was
used for calibration. Minimal lumen diameter, percent
diameter stenosis by QCA analysis, reference diameter, and
lesion length were measured preferably on end-diastolic
images. In our laboratory, coronary artery diameter mea-
surements performed with the ACOM.PC 5.01 system
have an interobserver variability of 0.11 mm and an intra-
observer variability of 0.08 mm for mean lumen diameter on
repeated analysis of the same frame (16).
Pressure measurements. After administration of intrave-
ous heparin 100 IU/kg, a pressure-monitoring guide wire
PressureWire, St. Jude Medical, Uppsala, Sweden) was
alibrated and introduced into the guiding catheter. The
ire was advanced up to the tip of the guiding catheter, and
t was verified that the pressure measured by the pressure-
onitoring guide wire was equal to the pressure measured
y the guiding catheter. Next, the wire was advanced into
he LAD until the pressure sensor was located in the mid to
istal part of the LAD. Adenosine was administered to
nduce maximum hyperemia, either intravenously (140
g/kg/min) or by intracoronary bolus (50 to 150 g).
ractional flow reserve was calculated as the ratio of mean
yperemic distal coronary pressure measured by the
ressure-monitoring guide wire to mean aortic pressure
easured by the guiding catheter. The measurement was
erformed twice, and FFR was taken as the average of both
easurements.
Clinical follow-up. Patients were sent a written question-
naire to report their clinical events. When needed, patients
and/or their general practitioners were contacted by phone
for additional information. If no satisfactory answer was
obtained, information was obtained from the Belgian na-
tional population registry. Major adverse events were death
from any cause, nonfatal myocardial infarction, or the need
for revascularization of the LAD (either by CABG or by
PCI). The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
The 5-year survival in the medical group was compared
with the survival of an age- and sex-matched reference
population, namely the Rotterdam Study. The characteris-
tics of this population are described in details elsewhere
(17). In brief, the Rotterdam Study is a prospective cohort
study ongoing since 1990 in the city of Rotterdam in the
Netherlands. The objective of the Rotterdam Study is to
study the incidence and risk factors of a variety of diseases,
such as cardiovascular, endocrine, hepatic, neurological,
ophthalmic, psychiatric, and respiratory. As of 2008, 14,926
subjects, age 45 years or older, comprise the Rotterdam
Study cohort. The Rotterdam Study cohort was chosen as areference population, primarily because this cohort guaran-
tees complete follow-up, including death. Second, health
care and clinical practice are similar in the Netherlands and
in Belgium, which is crucial to compare survival. For each
patient from the Aalst medical group, we considered age
and sex at study entry, and randomly selected 4 controls
from the Rotterdam Study, matched by age and sex.
Statistical analysis. All analyses were performed with
GraphPad Prism software, version 5 (GraphPad Software,
La Jolla, California) and SPSS software, version 16.0
(SPSS/IBM, Armonk, New York). Summary descriptive
statistics are reported as mean (SD) or counts (%), as
appropriate. Continuous variables were compared between
the 2 groups by independent samples t tests, and categorical
variables were compared with Fisher exact or chi-square
tests, as appropriate. The dependent variable in the analysis
was time to first event during follow-up. Kaplan-Meier
product limit curves for survival and major cardiac event-
free survival were constructed and compared between the
medical and the revascularization groups with the log-rank
test. For the medical group of patients, Kaplan-Meier
curves were also constructed and log-rank compared to
provide a univariate assessment of the prognostic value of
selected clinical and angiographic potential risk-factors.
Variables with p  0.2 at the univariate level were tested
ultivariately with a stepwise Cox proportional hazards
egression model to determine which ones contain indepen-
ent prognostic information. The thresholds for entry into
nd removal from the model were 5% and 10%, respectively.
conditional Cox regression analysis was conducted to
alculate the hazard ratio of dying for the Aalst versus the
otterdam population. All statistical tests were carried out
t the 5% level of significance.
esults
Baseline clinical and angiographic characteristics. There
were no differences in baseline clinical characteristics between
the 2 groups except for sex and smoking habits (Table 1).
Angiographic and hemodynamic data. Figure 2 shows the
correlation between the FFR values and the diameter
stenosis as assessed by either visual estimate (Fig. 2A) or
QCA (Fig. 2B). Mean FFR was 0.87 0.05 in the medical
group and 0.71  0.08 in the revascularization group. The
mean diameter stenosis assessed by visual estimate was
significantly lower in the medical group (39.8  10.4%)
than in the revascularization group (54.0  12.1%, p 
0.0001), but a large overlap of the values was present
between the 2 groups. The mean diameter stenosis by QCA
was also significantly lower in the medical group (38.5 
14.2%) than in the revascularization group (54.4  12.6%,
p  0.0001), but the overlap between hemodynamically
significant and nonsignificant stenoses was markedly less
pronounced than for visual estimate. In the medical group,
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1178127 patients (23%) had a diameter stenosis 50%. The
sensitivity, specificity, positive and negative predictive val-
ues, and diagnostic accuracy of 50% diameter stenosis by
visual estimate to predict an FFR value 0.80 were 77%,
73%, 45%, 92%, and 74%, respectively. The sensitivity,
specificity, positive and negative predictive values, and
diagnostic accuracy of 50% diameter stenosis by QCA
analysis were 68%, 80%, 55%, 87%, and 77%, respectively.
Clinical follow-up. The 5-year survival estimates were sim-
lar for patients in the medical group and for age- and
ex-matched controls (92.9% vs. 89.6%, respectively, p 
.74). The hazard ratio (HR) of dying for the Rotterdam
opulation versus the Aalst population was not statistically
ignificant (HR Aalst: 1.03, 95% confidence interval [CI]:
.68 to 1.57, p  0.87) (Fig. 3).
In the revascularization group, 13% had CABG and 87%
ad PCI (25% using drug-eluting stents). Complete
Table 1. Baseline Clinical Characteristics and Stenosis Characteristics
of the Patients in the Medical Group and the Revascularization Group
Medical Group
(n  564)
Revascularization Group
(n  166) p Value
Age, yrs 68.7 10.9 67.4 10.1 0.207
Male 55% 76% 0.0001
BMI, kg/m2 26.8 4.4 26.9 4.1 0.747
Diabetes 16.8% 18.7% 0.641
Smoking habits 35.3% 45.8% 0.018
Hyperlipidemia 57.6% 58.4% 0.929
Hypertension 50.5% 48.8% 0.66
Family history of CAD 5.7% 8.4% 0.207
Aspirin 75.5% 87.8% 0.117
Statin 63.3% 61.2% 0.834
Beta-blockers 53.1% 57.1% 0.684
ACE-inhibitors/ARB 32.7% 38.8% 0.527
CCS class 1.8 0.9 2.0 1 0.164
NYHA functional class 1.5 0.8 1.3 0.9 0.235
LVEF 70.6% 13.6% 68.8% 15.1% 0.227
30% 2.5% 1.9%
30%–50% 8.5% 7.1%
50% 89.0% 91.0%
LVEDP, mm Hg 15.4 8.4 14.9 6.2 0.504
Diameter stenosis 39.8% 10.4% 54.0% 12.1%
Range 30%–70% 30%–90% 0.0001
30%–50% 77.3% 23.6%
50%–70% 22.6% 76.4%
Pa, mm Hg 93.6 17.8 90.7 17. 70.07
Pd, mm Hg 82.2 17.0 64.6 14.5 0.0001
FFR 0.87 0.05 0.71 0.08
Values are mean SD or %.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; BMIbodymass
index; CAD coronary artery disease; CCS Canadian Cardiovascular Society; FFR fractional
flow reserve; FU follow-up; LVEDP left ventricular end-diastolic pressure; LVEF left ventric-
ular ejection fraction;NYHANewYorkHeartAssociation; Pameanaortic pressure; Pdmean
pressure distal to the stenosis.ollow-up was obtained in 100% of patients for survival and7% for event-free survival. The median follow-up for the
urvival endpoint was 39  18 months in the medical group
nd 37  19 months in the revascularization group (p 
.342). The mean follow-up for survival free from major
dverse cardiac events (MACE) was 38  18 months in the
edical group and 36  19 months in the revascularization
roup (p  0.25).
In the medical group, 30 (5.3%) patients died during
ollow-up. There were 2 (0.4%) myocardial infarctions, and
1 (2.0%) patients needed revascularization. In the revascu-
arization group, 16 (9.6%) died during follow-up, there
ere 2 (1.2%) myocardial infarctions, and 26 (15.9%)
atients needed revascularization. The Kaplan-Meier per-
ent survival estimates at 5 years were 92.9% in the medical
roup and 87.4% in the revascularization group (p  0.03)
Fig. 4A). The Kaplan-Meier percent survival free of death
r myocardial infarction estimate at 5 years was 92.0% in the
edical group versus 84.9% in the revascularization group
Fig. 4B). The Kaplan-Meier percent survival free of death,
yocardial infarction, or target vessel revascularization es-
imate at 5 years was 89.7% in the medical group versus
8.5% in the revascularization group (p  0.0019)
Fig. 4C). By multivariate analysis, age emerged as the only
ndependent predictive factor for MACE (HR: 1.039, 95%
I: 1.005 to 1.073; log-rank p  0.023) in the medical
roup. For the revascularization group, diabetes was the
nly significant independent predictive factor for MACE
HR: 2.88, 95% CI: 1.01 to 8.21; log-rank p  0.048), age
as at the limit of significance (HR: 1.05, 95% CI: 0.99 to
.11; log-rank p  0.065).
Among the 564 patients in the medical group, 127 (23%)
ad a diameter stenosis 50% by visual estimate. Their
aplan-Meier percent survival estimate free of events at 5
ears was similar to that in patients with a proximal LAD
iameter stenosis50% (92.1% vs. 88.8%, respectively, p
.42) (Fig. 5).
iscussion
This study indicates that patients with an angiographically
dubious, but hemodynamically nonsignificant, isolated ste-
nosis in the proximal LAD (as assessed in the catheteriza-
tion laboratory by FFR measurements) have a favorable
long-term outcome without mechanical revascularization.
Indeed, patients with an FFR 0.8 in an isolated proximal
LAD stenosis have a 92.0% survival estimate at 5 years.
This 92.0% survival estimate is comparable to that ob-
served in age- and sex-matched control individuals. We
observed 30 deaths (all-cause mortality) in the medical
group during the mean follow-up of 39 months, which
corresponds to an annual death rate of 1.63%. This value is
similar to the 1.5% annual death rate recently reported in
individuals without known coronary artery disease but with
multiple risk factors (3) (17).
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1179In the present study, the survival free of MACE (all-
cause mortality, myocardial infarction, and target vessel
revascularization) of patients in the medical group was
89.7%. This value is higher than in similar patients but with
a hemodynamically significant stenosis (FFR 0.80) and in
whom revascularization was performed.
The present study extends the data of the randomized
controlled DEFER trial in which patients with a hemody-
namically nonsignificant stenosis were randomized to re-
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Figure 3. Kaplan-Meier Estimates for the Medical and Control Group
Patients in the medical group are compared with age- and sex-matched
individuals from the Rotterdam Study (17).ceive PCI or to be treated medically. The trial showed no
superiority of PCI over conservative treatment in patients
with 1-vessel disease and a hemodynamically nonsignificant
stenosis (9). The present data extend the results of the
DEFER trial because the number of patients with a
nonsignificant stenosis is almost 6 times larger than in
DEFER and because more than 10 times the number of
patients with a proximal LAD were included. Hamilos et al.
(16) showed that when angiographically equivocal left main
coronary artery stenoses are hemodynamically nonsignifi-
cant, the clinical outcome is favorable without CABG. The
FAME (Fractional Flow Reserve versus Angiography for
Multivessel Evaluation) trial also indicated that in patients
with multivessel disease, PCI with drug-eluting stents that
were restricted only to stenoses able to induce myocardial
ischemia was associated with an approximately 30% reduc-
tion in death, myocardial infarction, and/or the need for a
new revascularization after 1 and 2 years (8,13).
Clinical practice guidelines currently recommend revas-
cularization when stress testing reveals myocardial ischemia.
Therefore, assessing the presence or absence of myocardial
ischemia by stress electrocardiography or imaging remains
central to determine the appropriateness of revascularization
therapy in patients with stable coronary artery disease
(1,18). This approach is justified by studies demonstrating
that a patient’s outcome depends on the presence and extent
of ischemia (19,20). In addition, the outcome benefit from
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1180extent of demonstrable ischemia before intervention
(21,22). Despite the apparent central role of ischemia, data
derived from privately insured patients’ insurance-claims
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Figure 4. Kaplan-Meier Estimates for the Medical and the
Revascularization Group
Shown are percent survival (A), percent survival free from death or myocar-
dial infarction (B), and survival free of major adverse cardiac events (death,
myocardial infarction, or target vessel revascularization) (C).databases or Medicare databases have shown that more than50% of patients with stable coronary artery disease lack an
objective definition of ischemia by noninvasive testing before
PCI (23,24). This disconnect between recommendation and
clinical practice is not necessarily probative of misutilization
(25). Indeed, in daily practice, a variety of clinical factors limit
the feasibility and the spatial accuracy—and therefore the
clinical usefulness—of noninvasive stress testing. These fac-
tors, rarely acknowledged in trials and meta-analyses, include
obesity, advanced age, orthopedic problems, the presence of a
bundle branch block, decreased left ventricular function, diffuse
disease, the coexistence of valvular disease, the presence of left
ventricular hypertrophy, or a prior myocardial infarction. These
factors certainly contribute to the fact that a sizable proportion
of patients undergo coronary angiography before functional
testing. The latter may come second and, in many patients, will
never come at all. FFR makes it possible to obtain both
anatomic and functional data during the same examination
(catheterization session).
After the left main coronary artery, the proximal LAD is
the segment with the largest distribution area. It is therefore
generally accepted that the presence of a stenosis in the
proximal LAD weighs more in the prognosis than any other
coronary segment (15,26). The presence of a narrowing of
more than 50% luminal reduction in the proximal segment
of the left anterior coronary artery often triggers a revascu-
larization procedure (18,27). Hannan et al. (28) showed that
approximately one-third of multivessel disease patients in-
dicated for CABG according to the guidelines, actually
received PCI. Yet, the presence of a stenosis in the proximal
LAD often tipped the balance toward CABG (28,29). The
present data also confirm the very poor relationship between
the angiographic appearance of a coronary stenosis and its
hemodynamic significance (16,30,31). Almost one-half of
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Figure 5. Kaplan-Meier Estimates in the Medical Group According
to Percent Diameter Stenosis
Patients with a fractional ﬂow reserve 0.80 are compared according to
the percent diameter stenosis (DS) by visual estimate.the stenoses gauged by visual estimate to be between 50% and
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118170% were hemodynamically nonsignificant, whereas 10% of
lesions between 30% and 50% were hemodynamically signifi-
cant. On top of the intrinsic inaccuracies of the angiogram, the
latter morphological approach of vessel dimension does not
take into account the myocardial mass supplied by the vessel: a
similar degree of stenosis at angiography will have a different
functional significance depending on the extent of perfused
myocardial mass. In contrast, pressure-derived FFR measure-
ments integrate both vessel anatomy and myocardial mass, as
well as the contribution of collateral circulation. Practically, this
indicates that when revascularization is based mainly on an-
giographic guidance, it is unavoidable that a number of
hemodynamically nonsignificant stenoses will be revascular-
ized, whereas a number of stenoses deemed nonsignificant will
be deferred inappropriately (7–9,32).
Study limitations. This observational study has the limita-
tions inherent to nonrandomized trials. The comparison
was made between 2 patient populations in whom the
treatment strategy was different and determined upfront by
the measurement of FFR. The study does not indicate that
the decision to revascularize stenoses with an FFR lower
than 0.80 was justified. However, during the recruitment
period (1999 to 2008), we felt it inappropriate not to
propose revascularization to patients presenting with com-
plaints and a hemodynamically significant stenosis in the
proximal LAD.
Another caveat is that only a very low number (5.8%) of
patients with non–myocardial infarction acute coronary
syndromes are included. The conclusions should, therefore,
be restricted to patients with stable coronary artery disease.
Outcomes regarding different routes of adenosine adminis-
tration also are not provided.
Finally, a large number of patients with a stenosis of
50% were included in this registry, although in these
stenoses, revascularization is generally not contemplated.
Yet, the data show, on the contrary, that in a large artery
such as the proximal LAD, the angiogram often underes-
timates the true severity of the stenosis.
Conclusions
In patients with an isolated stenosis in the proximal LAD that
is angiographically equivocal but unable to induce myocardial
ischemia as assessed by FFR, medical treatment is associated
with a favorable clinical outcome after 3 to 5 years. This
finding supports the strategy of deciding about revasculariza-
tion based on both anatomic and functional information
obtained simultaneously in the catheterization laboratory.
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